tag:blogger.com,1999:blog-19490962.post7673711013537696153..comments2023-12-10T10:06:41.979+00:00Comments on mutations of mortality: CLL Treatment: Purine analoguesTerry Hamblinhttp://www.blogger.com/profile/06346629921055055879noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-19490962.post-36912754568628409472008-04-07T01:44:00.000+01:002008-04-07T01:44:00.000+01:00And I for one am very appreciative of the effort. ...And I for one am very appreciative of the effort. I enjoy getting your perspective. Reading abstracts without the depth of knowledge you have is a hit-or-miss affair; sometimes you miss the forest for the minutiae of the trees (or the duff on the forest floor for that matter).Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-19490962.post-90719170709771666892008-04-06T09:12:00.000+01:002008-04-06T09:12:00.000+01:00In these articles I am trying to report what has b...In these articles I am trying to report what has been established by phase III trials, or when these are unavailable the best available evidence. This is not a comprehensive review of all possible treatments.Terry Hamblinhttps://www.blogger.com/profile/06346629921055055879noreply@blogger.comtag:blogger.com,1999:blog-19490962.post-11178911041446399962008-04-06T09:10:00.000+01:002008-04-06T09:10:00.000+01:00Mitoxantrone is very similar to adriamycin - it is...Mitoxantrone is very similar to adriamycin - it is blue rather than red - but it is reputed to be less likley to cause hair loss and perhaps be less toxic to patients, though this might just be a matter of dose. Adriamycin has long been used in CLL - in France they insist that a regien that includes half dose adriamycin is extremely effective. Mitoxantrone was first introduced in Spain as FCM. It gave responses as good as FCR. Currently there are trials looking at FCMR.Terry Hamblinhttps://www.blogger.com/profile/06346629921055055879noreply@blogger.comtag:blogger.com,1999:blog-19490962.post-63017718570552281442008-04-06T02:50:00.000+01:002008-04-06T02:50:00.000+01:00It certainly would be difficult to quantify 'quali...It certainly would be difficult to quantify 'quality of life', but I can tell you that patients can experience it very vividly, even if they can't put the positive changes in number form.<BR/><BR/>It's interesting that I've never encountered a discussion of mitoxantrone with any hematologist I've consulted. Is this a UK or continental drug (in lieu of drugs available elsewhere)?<BR/><BR/>Anyway, I'm passed the point where such a drug would help, so it's a moot point for me.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-19490962.post-32683307179748308542008-04-05T09:10:00.000+01:002008-04-05T09:10:00.000+01:00One small, flawed, phase II trial from MD Anderson...One small, flawed, phase II trial from MD Anderson CC. It is amazing how people are taken in. Mitoxantrone trials continue and are quite encouraging. <BR/><BR/>It is quite difficult to demonstrate that quality of life is better in patients who have a single remission compared to that of patients who have two yet live the same time.Terry Hamblinhttps://www.blogger.com/profile/06346629921055055879noreply@blogger.comtag:blogger.com,1999:blog-19490962.post-73639788780542590962008-04-05T03:54:00.000+01:002008-04-05T03:54:00.000+01:00Didn't subsequent trials show little or no value t...Didn't subsequent trials show little or no value to the addition of mitoxantrone? That is my recollection, at least. The drug has some history in clinical trials for CLL, that I do know.<BR/><BR/>One thing that is left unsaid here is that longer complete remissions and progression-free survival can be accompanied by a better quality of life. <BR/><BR/>With CLL, often that is all that one can hope for. That, and a quick and painless end.Anonymousnoreply@blogger.com